FDA Expected to Announce Decision on INO-3107 for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has an anticipated decision date of October 30, 2026, for Inovio Pharmaceuticals' INO-3107. This DNA immunotherapy is under review for the treatment of recurrent respiratory papillomatosis (RRP), a rare condition characterized by recurrent wart-like growths in the respiratory tract.